🍪 CompoundTalk uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsMetabolic Health & DiabetesSURPASS-CVOT: tirzepatide cardiovascular outcomes trial design — looking for input Page 6

SURPASS-CVOT: tirzepatide cardiovascular outcomes trial design — looking for input

Admin Sat, Jul 12, 2025 at 7:09 AM 40 replies 1,896 viewsPage 6 of 8
PharmD_Rodriguez
Senior Member
3,456
14,567
Jan 2024
Miami, FL
Oct 21, 2025 at 6:18 PM#26
josh_phd_bmore said:
If you are going to change something, change one thing and give it long enough to express itself.

Thank you — that is the clearest version of this I have read, and I have read a lot of them. Taking it to my next appointment.

Last edited: Oct 21, 2025 at 11:18 PM
7 5paul_denver, TinaHashiRN, robert_kc and 4 others
Reply Quote Save Share Report
Dr.ReproEndo
Senior Member
1,890
8,901
Jan 2024
Scottsdale, AZ
Nov 4, 2025 at 8:34 AM#27

From the other side of the consultation, briefly. The mechanism and the magnitude are separate questions. Agreeing that something happens says nothing about whether it happens enough to act on.

8 6andrew_nyc, Dr.EndoEP, GraceAZ_72 and 5 others
Reply Quote Save Share Report
lori_vegas
Member
378
1,678
Aug 2024
Las Vegas, NV
Nov 17, 2025 at 10:42 PM#28
Dr.ReproEndo said:
The mechanism and the magnitude are separate questions.

This is my experience too, for whatever a second data point is worth. Posting only so the count is not one.

9 7oliver_london, tane_welly, Dr.PathRoch and 6 others
Reply Quote Save Share Report

Sigma-Aldrich — Research-Grade Standards

Certified reference materials, analytical reagents, and research-grade standards for peptide verification. Trusted by laboratories worldwide.

Shop Reference Standards
TirzTom
Senior Member
2,789
9,876
Feb 2024
Florida
Online
Dec 1, 2025 at 12:42 PM#29
Dr.ReproEndo said:
The mechanism and the magnitude are separate questions.

There is a second half to this that has not been said yet. The version of this that has an answer is narrower than the version being asked. Narrow it and it becomes tractable; leave it broad and the thread will produce nine confident and incompatible replies.

Last edited: Dec 1, 2025 at 4:42 PM
10 8SandraNC_45, Dr.EndoIndy, tom_AK and 7 others
Reply Quote Save Share Report
Admin
Administrator
2,456
9,812
Oct 2023
Online
Dec 15, 2025 at 2:35 AM#30

Reporting back.

Update, and it is the boring outcome: nothing was wrong. The measurement I was reading had moved less than its own week-to-week variation, which somebody said upthread and I did not believe.

Last edited: Dec 15, 2025 at 6:35 AM
32 5PeptideSynthNJ, Dr.KarenChen, Dr.NateNeph and 29 others
Reply Quote Save Share Report

Similar Threads

SUSTAIN-6 to SELECT — the cardiovascular evidence timeline14 replies
GLP-1 and insulin resistance — HOMA-IR improvement data17 replies
Metabolic syndrome reversal criteria — how GLP-1 addresses all 55 replies
A1C target achievement rates — sema vs tirz comparison8 replies
SURPASS-CVOT: tirzepatide cardiovascular outcomes trial design3 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register